Zai Lab Stock Forecast, Price & News

Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions

Is Zai Lab a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Zai Lab stock.
View analyst ratings for Zai Lab or view top-rated stocks.

What stocks does MarketBeat like better than Zai Lab?

Wall Street analysts have given Zai Lab a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zai Lab wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) released its earnings results on Monday, August, 9th. The company reported ($1.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.55) by $0.21. The business had revenue of $36.94 million for the quarter, compared to analysts' expectations of $24.20 million.
View Zai Lab's earnings history.

How has Zai Lab's stock price been impacted by Coronavirus (COVID-19)?

Zai Lab's stock was trading at $50.13 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZLAB shares have increased by 103.5% and is now trading at $102.00.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ZLAB?

5 equities research analysts have issued twelve-month price objectives for Zai Lab's shares. Their forecasts range from $111.00 to $250.00. On average, they expect Zai Lab's stock price to reach $199.85 in the next year. This suggests a possible upside of 95.9% from the stock's current price.
View analysts' price targets for Zai Lab or view top-rated stocks among Wall Street analysts.

Who are Zai Lab's key executives?

Zai Lab's management team includes the following people:

• Ying Du, Chairman & Chief Executive Officer (LinkedIn Profile)
• Tao Fu, President, Chief Operating Officer & Director
• Billy Cho, Chief Financial Officer
• Ning Xu, Executive VP & Head-Clinical Operations
• James Yan, Chief Operating Officer-Research & Development

Who are some of Zai Lab's key competitors?

Some companies that are related to Zai Lab include BeiGene (BGNE), Astellas Pharma (ALPMY), Genmab A/S (GNMSF), Genmab A/S (GMAB), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Shiseido (SSDOY), Horizon Therapeutics Public (HZNP), Alnylam Pharmaceuticals (ALNY), Royalty Pharma (RPRX), Takeda Pharmaceutical (TKPYY), Catalent (CTLT), UCB (UCBJF), Viatris (VTRS), Elanco Animal Health (ELAN) and BioMarin Pharmaceutical (BMRN).
View all of ZLAB's competitors.

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

When did Zai Lab IPO?

(ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by a variety of institutional and retail investors. Top institutional investors include Hamilton Lane Advisors LLC (0.01%) and Golden Green Inc. (0.00%). Company insiders that own Zai Lab stock include Harald Reinhart, John D Diekman, Kai-Xian Chen, Tao Fu, William Ki Chul Cho and Ying Du.
View institutional ownership trends for Zai Lab.

Which institutional investors are selling Zai Lab stock?

ZLAB stock was sold by a variety of institutional investors in the last quarter, including Golden Green Inc.. Company insiders that have sold Zai Lab company stock in the last year include Harald Reinhart, John D Diekman, Kai-Xian Chen, Tao Fu, William Ki Chul Cho, and Ying Du.
View insider buying and selling activity for Zai Lab or view top insider-selling stocks.

Which institutional investors are buying Zai Lab stock?

ZLAB stock was bought by a variety of institutional investors in the last quarter, including Hamilton Lane Advisors LLC.
View insider buying and selling activity for Zai Lab or or view top insider-buying stocks.

How do I buy shares of Zai Lab?

Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $102.00.

How much money does Zai Lab make?

Zai Lab has a market capitalization of $9.73 billion and generates $48.96 million in revenue each year. The company earns $-268.90 million in net income (profit) each year or ($3.46) on an earnings per share basis.

How many employees does Zai Lab have?

Zai Lab employs 2,020 workers across the globe.

What is Zai Lab's official website?

The official website for Zai Lab is www.zailaboratory.com.

Where are Zai Lab's headquarters?

Zai Lab is headquartered at 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210.

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 862161632588 or via email at [email protected].